JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB278723

Anti-MEK1 + MEK2 (phospho S218 + S222) antibody [MEK12S217S221-H2]

5

(2 Reviews)

|

(8 Publications)

Rabbit Recombinant Monoclonal MEK1 phospho S218 antibody. Suitable for Flow Cyt, WB and reacts with Human samples. Cited in 8 publications. Immunogen corresponding to Synthetic Peptide within Human MAP2K1 phospho S218.

View Alternative Names

MEK1, PRKMK1, MAP2K1, Dual specificity mitogen-activated protein kinase kinase 1, MAP kinase kinase 1, MAPKK 1, MKK1, ERK activator kinase 1, MAPK/ERK kinase 1, MEK 1

4 Images
Flow Cytometry - Anti-MEK1 + MEK2 (phospho S218 + S222) antibody [MEK12S217S221-H2] (AB278723)
  • Flow Cyt

Supplier Data

Flow Cytometry - Anti-MEK1 + MEK2 (phospho S218 + S222) antibody [MEK12S217S221-H2] (AB278723)

Flow cytometric analysis of Daudi cells secondary antibody only negative control (blue) or untreated (red) or treated with IFNa + IL-4 + pervanadate (green) using ab278723 at 0.01 µg/mL.

Flow Cytometry - Anti-MEK1 + MEK2 (phospho S218 + S222) antibody [MEK12S217S221-H2] (AB278723)
  • Flow Cyt

Supplier Data

Flow Cytometry - Anti-MEK1 + MEK2 (phospho S218 + S222) antibody [MEK12S217S221-H2] (AB278723)

Peptide blocking flow cytometric analysis of Daudi cells secondary antibody only negative control (light blue) or stained with isotype control (orange) or untreated (red) or treated with IFNa + IL-4 + pervanadate (green) or untreated and blocked with phospho peptide (gold) or treated and blocked with phospho peptide (black) or untreated and blocked with non-phospho peptide (dark blue) or treated and blocked with non-phospho peptide (purple) using ab278723 at 0.01 μg/mL.

Western blot - Anti-MEK1 + MEK2 (phospho S218 + S222) antibody [MEK12S217S221-H2] (AB278723)
  • WB

AbReview79115****

Western blot - Anti-MEK1 + MEK2 (phospho S218 + S222) antibody [MEK12S217S221-H2] (AB278723)

4-15% Gel. Blocking was done using 5% milk for 1 hour at 25°C

All lanes:

Western blot - Anti-MEK1 + MEK2 (phospho S218 + S222) antibody [MEK12S217S221-H2] (ab278723) at 1/1000 dilution

Lane 1:

HEK293T cells Serum starved overnight at 25 µg

Lane 2:

HEK293T cells Serum starved overnight then stimulated with EGF for 30 min at 25 µg

Secondary

All lanes:

HRP-conjugated affinipure goat anti-rabbit at 1/5000 dilution

false

This image is courtesy of an anonymous Abreview

Western blot - Anti-MEK1 + MEK2 (phospho S218 + S222) antibody [MEK12S217S221-H2] (AB278723)
  • WB

Supplier Data

Western blot - Anti-MEK1 + MEK2 (phospho S218 + S222) antibody [MEK12S217S221-H2] (AB278723)

All lanes:

Western blot - Anti-MEK1 + MEK2 (phospho S218 + S222) antibody [MEK12S217S221-H2] (ab278723) at 0.1 µg/mL

Lane 1:

HeLa cell extract treated with UV+TPA

Lane 2:

HeLa cell extract untreated with UV+TPA

Predicted band size: 43 kDa

false

  • 660 APC

    APC Anti-MEK1 + MEK2 (phospho S218 + S222) antibody [MEK12S217S221-H2]

  • 578 PE

    PE Anti-MEK1 + MEK2 (phospho S218 + S222) antibody [MEK12S217S221-H2]

  • 519 FITC

    FITC Anti-MEK1 + MEK2 (phospho S218 + S222) antibody [MEK12S217S221-H2]

Key facts

Host species

Rabbit

Clonality

Monoclonal

Clone number

MEK12S217S221-H2

Isotype

IgG

Light chain type

kappa

Carrier free

No

Reacts with

Human

Applications

WB, Flow Cyt

applications

Immunogen

Synthetic Peptide within Human MAP2K1 phospho S218. The exact immunogen used to generate this antibody is proprietary information.

Q02750

style
left-column

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "FlowCyt" : {"fullname" : "Flow Cytometry", "shortname":"Flow Cyt"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "FlowCyt-species-checked": "testedAndGuaranteed", "FlowCyt-species-dilution-info": "0.001-1 µg/mL", "FlowCyt-species-notes": "<p></p>", "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "0.001-1 µg/mL", "WB-species-notes": "<p></p>" } } }
style
left-column

Product details

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

  • - High batch-to-batch consistency and reproducibility
  • - Improved sensitivity and specificity
  • - Long-term security of supply
  • - Animal-free batch production

For more information, read more on recombinant antibodies.

style
left-column

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Protein A/G
Storage buffer
Preservative: 0.02% Sodium azide Constituents: PBS, 50% Glycerol (glycerin, glycerine), 0.1% BSA
Shipped at conditions
Blue Ice
Appropriate short-term storage duration
1-2 weeks
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle
style
left-column

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

MEK1 and MEK2 also known as MAP2K1 and MAP2K2 respectively are dual-specificity kinases that play roles in signaling pathways mediating cellular responses. MEK1 and MEK2 have molecular weights of approximately 45kDa. They are expressed in various tissues including the heart brain and skeletal muscles reflecting their widespread function within the organism. These proteins are often referred collectively as the MEK1/2 complex due to their shared and overlapping roles in cell signaling.
Biological function summary

MEK1 and MEK2 are integral parts of the mitogen-activated protein kinase (MAPK) signaling cascade. MEK1/2 phosphorylate and activate the ERK1/2 kinases which transmit signals from the cell surface to the nucleus regulating gene expression and cell fate decisions. The MEK1/2 proteins also act in concert with other kinases and substrates forming signaling complexes that ensure specific and regulated cellular outcomes.

Pathways

MEK1 and MEK2 play key roles within the MAPK/ERK pathway a critical signaling mechanism for cell division and survival. They also link to the RAS/MAPK pathway involved in transmitting signals from membrane receptors to the nucleus. In these pathways MEK1/2 interact with proteins like RAF kinases and ERK1/2 propagating signals that influence cellular growth and differentiation.

MEK1 and MEK2 are implicated in cancer and neurological disorders. Abnormal activity of the MEK1/2 proteins often due to mutations can lead to uncontrolled cell proliferation contributing to the development of cancers such as melanoma. In neurological disorders dysregulation of MEK1/2 signaling relates to conditions like neuro-cardio-facial-cutaneous syndromes. These proteins interact with other key players in these diseases such as mutant RAF proteins in melanoma highlighting their critical roles in disease mechanisms.
style
left-column
style
left-column

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:
style
left-column

Target data

Dual specificity protein kinase which acts as an essential component of the MAP kinase signal transduction pathway. Binding of extracellular ligands such as growth factors, cytokines and hormones to their cell-surface receptors activates RAS and this initiates RAF1 activation. RAF1 then further activates the dual-specificity protein kinases MAP2K1/MEK1 and MAP2K2/MEK2. Both MAP2K1/MEK1 and MAP2K2/MEK2 function specifically in the MAPK/ERK cascade, and catalyze the concomitant phosphorylation of a threonine and a tyrosine residue in a Thr-Glu-Tyr sequence located in the extracellular signal-regulated kinases MAPK3/ERK1 and MAPK1/ERK2, leading to their activation and further transduction of the signal within the MAPK/ERK cascade. Activates BRAF in a KSR1 or KSR2-dependent manner; by binding to KSR1 or KSR2 releases the inhibitory intramolecular interaction between KSR1 or KSR2 protein kinase and N-terminal domains which promotes KSR1 or KSR2-BRAF dimerization and BRAF activation (PubMed : 29433126). Depending on the cellular context, this pathway mediates diverse biological functions such as cell growth, adhesion, survival and differentiation, predominantly through the regulation of transcription, metabolism and cytoskeletal rearrangements. One target of the MAPK/ERK cascade is peroxisome proliferator-activated receptor gamma (PPARG), a nuclear receptor that promotes differentiation and apoptosis. MAP2K1/MEK1 has been shown to export PPARG from the nucleus. The MAPK/ERK cascade is also involved in the regulation of endosomal dynamics, including lysosome processing and endosome cycling through the perinuclear recycling compartment (PNRC), as well as in the fragmentation of the Golgi apparatus during mitosis.
See full target information MAP2K1 phospho S218

Additional targets

MAP2K2 phospho S222
style
left-column

Publications (8)

Recent publications for all applications. Explore the full list and refine your search

Journal of gastrointestinal oncology 16:1622-1634 PubMed40950356

2025

DDX18 promotes growth and metastasis of hepatocellular carcinoma via activating EMT and MAPK signaling.

Applications

Unspecified application

Species

Unspecified reactive species

Xiaodong Xu,Xiaoxia Yu,Nannan Zhang,Feiran Wang,Zhong Chen

Cell death & disease 16:231 PubMed40169556

2025

Mechanical sensing protein PIEZO1 controls osteoarthritis via glycolysis mediated mesenchymal stem cells-Th17 cells crosstalk.

Applications

Unspecified application

Species

Unspecified reactive species

Yikun Zhou,Mingzhao Li,Shuai Lin,Zilu Zhu,Zimeng Zhuang,Shengjie Cui,Liujing Chen,Ran Zhang,Xuedong Wang,Bo Shen,Chider Chen,Ruili Yang

iScience 27:110029 PubMed38883844

2024

Intracellular magnetic hyperthermia reverses sorafenib resistance in hepatocellular carcinoma through its action on signaling pathways.

Applications

Unspecified application

Species

Unspecified reactive species

Hugang Li,Zirui Ye,Xun Wang,Jianlan Yuan,Jingyi Guo,Chen Liu,Bin Yan,Haiming Fan,Yi Lyu,Xiaoli Liu

Molecular biotechnology 67:689-704 PubMed38456959

2024

O-sialoglycoprotein Endopeptidase (OSGEP) Suppresses Hepatic Ischemia-Reperfusion Injury-Induced Ferroptosis Through Modulating the MEK/ERK Signaling Pathway.

Applications

Unspecified application

Species

Unspecified reactive species

Yuanyuan Tao,Wanqing Zhou,Cheng Chen,Qian Zhang,Zhuoyi Liu,Pingping Xia,Zhi Ye,Chunling Li

Cell death & disease 14:212 PubMed36966163

2023

ZNF582 overexpression restrains the progression of clear cell renal cell carcinoma by enhancing the binding of TJP2 and ERK2 and inhibiting ERK2 phosphorylation.

Applications

Unspecified application

Species

Unspecified reactive species

Wuping Yang,Zedan Zhang,Lei Li,Kenan Zhang,Yawei Xu,Mancheng Xia,Jingcheng Zhou,Yanqing Gong,Jinchao Chen,Kan Gong

Experimental biology and medicine (Maywood, N.J.) 248:469-480 PubMed36852460

2023

LncRNA XLOC_015548 affects the proliferation and differentiation of myoblasts via the MAPK signaling pathway.

Applications

Unspecified application

Species

Unspecified reactive species

Yihao Wei,Tiantian Qi,Siyang Cao,Weifei Zhang,Fei Yu,Hui Zeng,Jian Weng

Pharmaceutical biology 60:764-773 PubMed35387566

2022

Caudatin blocks the proliferation, stemness and glycolysis of non-small cell lung cancer cells through the Raf/MEK/ERK pathway.

Applications

Unspecified application

Species

Unspecified reactive species

Juan Hou,Qing Chen,Yufeng Huang,Zhiwei Wu,De Ma

Cell death & disease 12:617 PubMed34131102

2021

METTL14 promotes tumorigenesis by regulating lncRNA OIP5-AS1/miR-98/ADAMTS8 signaling in papillary thyroid cancer.

Applications

Unspecified application

Species

Unspecified reactive species

Xiaoping Zhang,Dan Li,Chengyou Jia,Haidong Cai,Zhongwei Lv,Bo Wu
View all publications
style
left-column
style
left-column
style
right-column

Complementary Products

Primary Antibodies

AB184699

Anti-ERK1 + ERK2 antibody [EPR17526]

RabMAb|Recombinant|KO Validated|20ul selling size

Immunocytochemistry/ Immunofluorescence - Anti-ERK1 + ERK2 antibody [EPR17526] (AB184699)

  • 5
  • 1
Primary Antibodies

AB278538

Anti-ERK1 (phospho T202 + Y204) + ERK2 (phospho T185 + Y187) antibody [ERK12T202Y204-A11]

20ul selling size|Recombinant|Lab Essentials

Flow Cytometry - Anti-ERK1 (phospho T202 + Y204) + ERK2 (phospho T185 + Y187) antibody [ERK12T202Y204-A11] (AB278538)

  • 0
  • 0
Primary Antibodies

AB178876

Anti-MEK1 + MEK2 antibody [EPR16667]

20ul selling size|RabMAb|Recombinant

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-MEK1 + MEK2 antibody [EPR16667] (AB178876)

  • 5
  • 1
Primary Antibodies

AB201015

Anti-ERK1 (phospho T202) + ERK2 (phospho T185) antibody [EPR19401]

RabMAb|Recombinant|20ul selling size

Immunocytochemistry/ Immunofluorescence - Anti-ERK1 (phospho T202) + ERK2 (phospho T185) antibody [EPR19401] (AB201015)

  • 4
  • 4

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com